Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy—a proof of concept analysis

References

• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013;15:S3–S10
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Gastrointestinal Drugs Advisor Committee (GIDAC). Advisory Meeting, Hilton Washington DC/North, Gaithersburg, VA, November 4, 2010
   Google Scholar
• Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62:1592–601
   PubMed Web of Science ®Google Scholar
• Chang CH, Chen HC, Lin JW, et al. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:763–71
   Google Scholar
• Niculescu L, Li C, Huang J, et al. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 2009;25:729–40
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003;49:508–18
   PubMed Web of Science ®Google Scholar
• Yilmaz H, Gurel S, Ozdemir O. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol 2005;16:138–42
   PubMedGoogle Scholar
• DUEXIS® Prescribing information. Horizon Pharma, Inc.; 2012
   Google Scholar
• VIMOVO® Prescribing Information. AstraZeneca LP; 2012
   Google Scholar
• Arthrotec® Prescribing Information. Pfizer; 2013
   Google Scholar
• Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J 2012;105:613–8
   Google Scholar
• Hunyady B, Juricskay I, Nagy L, et al. Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry. Eur J Clin Pharmacol 1996;50:449–56
   Google Scholar
• Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exper Pharmacol Physiol 1996;23:432–4
   PubMed Web of Science ®Google Scholar
• Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? Gastroenterology 1990;99:345–51
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011;27:1243–53
   PubMed Web of Science ®Google Scholar
• Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379–86
   Google Scholar
• Schiff M, Peura D. HZT-501 (DUEXIS®; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol 2012;6:25–35
   PubMed Web of Science ®Google Scholar
• Chremos AN. Pharmacodynamics of famotidine. Am J Med 1986;81:3–7
   Google Scholar
• Echizen H, Shòda R, Umeda N, et al. Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects. Clin Pharmacol Ther 1988;44:690–8
   PubMed Web of Science ®Google Scholar
• Data on File, 2010. Horizon Pharma, Inc. Study HZ-CA-017, submitted to FDA as part of approved IND # 72,116
   Google Scholar
• Nishino M, Sugimoto M, Kodaira C, et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori negative healthy volunteers. J Clin Pharmacol 2011;51:1079–86
   PubMed Web of Science ®Google Scholar
• Yeomans ND. New data on healing of nonsteroidal anti-inflammatory drug associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 1998;104:56S–61S
   Google Scholar
• Miner P, Plachetka J, Orlemans E, et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, phase 1 study in healthy volunteers. Aliment Pharmacol Ther 2010;32:414–24
   PubMed Web of Science ®Google Scholar
• Miner PB, Allgood LD. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther 2007;25:103–9
   PubMed Web of Science ®Google Scholar
• Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. NEJM 1996;334:1435–9
   PubMed Web of Science ®Google Scholar